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Abstract: The adjuvant treatment of women with endocrine-sensitive early breast cancer has 
been dominated for the last 40 years by tamoxifen. However, the side-effects associated with this 
therapy have prompted a search for safer and biochemically more selective endocrine agents and 
led to the development of the third-generation aromatase inhibitors (AIs) anastrozole, letrozole 
and exemestane. Promising results in advanced disease have paved the way for treating early 
breast cancer, and AIs are increasingly replacing tamoxifen in the adjuvant setting. Several 
large, randomized trials with AIs have been completed or are ongoing in women with early-stage 
breast cancer, documenting the signiﬁ  cant impact that these drugs are making on the risk for 
recurrence of breast cancer. As a result, there is increasing and widespread use of AI therapy 
for the treatment of early-stage endocrine-responsive breast cancer. This review summarizes 
the data for exemestane in the adjuvant setting, showing that a switch to exemestane after 2 to 
3 years of tamoxifen therapy is associated with a statistically signiﬁ  cant survival beneﬁ  t and is 
regarded as being sensitive by international and national experts.
Keywords: early breast cancer, adjuvant setting, endocrine-sensitive, tamoxifen, aromatase 
inhibitor, exemestane, switch, IES 31, NSABP B-33, TEAM
Despite the improvement in survival observed with tamoxifen, a considerable 
proportion of women with endocrine-sensitive breast cancer do not appear to beneﬁ  t 
from the orally active selective estrogen receptor modulator (SERM): more than half 
of the women experience breast cancer relapses and more than two thirds of deaths 
occur after the initial 5 years after surgery (Early Breast Cancer Trialists’ Collaborative 
Group 1998, 2005, 2007).
Laboratory studies indicate that a reduction in the antagonist properties of tamoxifen 
could be caused by the up-regulation of tyrosine kinase receptors, especially HER2 and 
epidermal growth-factor receptors (EGFR), downstream protein kinases, or both, resulting 
in either primary or adaptive/acquired resistance to tamoxifen (Osborne et al 2003; Shou 
et al 2004). In addition, tamoxifen-treated patients may be exposed to a modest increased 
risk of vaginal bleeding, endometrial cancer, and venous thrombosis.
These limitations have prompted the search for alternative endocrine therapies with 
increased efﬁ  cacy and fewer long-term complications and led to the development of 
anti-aromatase inhibitors (AIs). These compounds work by blocking the aromatase enzyme 
in the ﬁ  nal step of estrogen synthesis, thus lowering circulating estrogen levels. The AIs in 
clinical use today include the third-generation steroidal irreversible, type I AI exemestane 
and the nonsteroidal reversible, type II AIs anastrozole and letrozole. The suppression 
of circulating estrogen is profound, approximately 95% to 98% with all third-generation 
AIs (Geisler et al 1998). This is the general explanation for the observed better efﬁ  cacy 
of aromatase inhibitors compared to tamoxifen. In addition, AIs inhibit the cytochrome 
P450-dependent aromatase enzyme, lacking tamoxifen’s partial agonist activity.
Tamoxifen is partly metabolized by CYP enzymes. Decreased CYP2D6-
metabolism, either because of mutations in the CYP2D6 gene and/or because of Therapeutics and Clinical Risk Management 2008:4(6) 1296
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comedication with CYP2D6 inhibitors, may result in a 
decreased efﬁ  cacy of the drug (Jin et al 2005). In the respec-
tive group of these individuals it is hypothesized that the 
use of CYP2D6 independently metabolized drugs such as 
AIs may be beneﬁ  cial. Clinical studies to clarify this issue 
are ongoing.
Pharmacology of exemestane
Exemestane is an irreversible, steroidal aromatase inactivator, 
structurally related to the natural substrate androstenedione. 
It acts as a false substrate for the aromatase enzyme, and is 
processed to an intermediate that binds irreversibly to the 
active site of the enzyme causing its inactivation, an effect 
also known as “suicide inhibition” (Dank 2002; Dixon 
2004). Exemestane signiﬁ  cantly lowers circulating estrogen 
concentrations: after a single oral dose of 25 mg the levels of 
estrogen, estradiol, and estrogen-sulfate decrease by 85% to 
95% after 2 to 3 days and persist up to 5 days (Johannessen 
et al 1997). Exemestane has no detectable effect on adrenal 
biosynthesis of corticosteroids, aldosterone, or on other 
enzymes involved in the steroidogenic pathway up to a 
concentration at least 600 times higher than that inhibiting 
the aromatase enzyme (Dixon 2004).
The recommended dosage of exemestane is 25 mg taken 
orally once daily after a meal which is rapidly absorbed 
with a maximum plasma concentration observed within 
2 hours of ingestion (Evans 1992). Exemestane is distributed 
extensively into tissues and is 90% bound to plasma proteins, 
steady-state conditions are attained by 7 days (Clemett 
and Lamb 2000). The agent is metabolized by CYP3A4 to 
compounds that are inactive or show minimal inhibition 
of aromatase (Wong and Pritchard 2005). Excretion of 
exemestane is via the urine and faeces, with 1% of the drug 
being excreted unchanged in urine. Although the area under 
the curve (AUC) of exemestane after a single 25-mg dose 
is elevated 3-fold in severe renal or liver dysfunction, dose 
reduction is not required as the drug is well tolerated in breast 
cancer patients at even 8- to 24-fold higher than the recom-
mended dose (Wong and Pritchard 2005).
Exemestane in the adjuvant setting
The efﬁ  cacy of exemestane in the treatment of women 
with early breast cancer was evaluated in 3 large ran-
domized trials. A third study is in progress. Exemes-
tane was approved in the US and European Union for 
the adjuvant treatment of postmenopausal women with 
endocrine-sensitive early breast cancer who have received 
2 to 3 years of tamoxifen and are switched to exemestane 
for the completion of a total of 5 consecutive years of 
adjuvant hormonal therapy.
Intergroup study IES 31
The approval was based on the data of the double-blind, 
randomized, adjuvant Intergroup Exemestane Study (IES) 
comparing 5 years of tamoxifen with the sequential use 
of tamoxifen followed by exemestane for a total treatment 
duration of 5 years. The trial included 4,742 postmenopausal 
patients from 37 countries and 20 co-operative groups with 
endocrine-sensitive early completely resected breast cancer. 
All of them were disease free after 2 to 3 years of tamoxifen 
and were randomized in the intent-to-treat (ITT) analysis to 
receive either tamoxifen once daily at the same dose received 
before randomization (N = 2,372) or exemestane (5 mg once 
daily; N = 2,352). The endocrine therapy was ﬁ  nished after 
5 years (Figure 1).
The primary end point was disease-free survival (DFS), 
deﬁ  ned as the time from randomization to time of local or 
distant recurrence of breast cancer, contralateral invasive 
breast cancer, or death from any cause. Secondary end points 
included overall survival (OS), the incidence of contralateral 
breast cancer, and long- term tolerability.
The ﬁ  rst planned interim analysis after a median follow-up 
of 30.6 months showed a signiﬁ  cant improvement in DFS, 
relatively by 32%, absolutely by 4.7% (unadjusted hazard 
ratio [HR] 0.68; 95% conﬁ  dence interval [CI] 0.56–0.82; 
p  0.001) (Coombes et al 2004). DFS 3 years after 
randomization was 91.5% (95% CI 90.0–92.7) in the 
exemestane group and 86.8% (95% CI 85.1–88.3) in the 
tamoxifen group. Furthermore, the AI proved to be signiﬁ  -
cantly more efﬁ  cient than tamoxifen in all subgroups, deﬁ  ned 
according to estrogen-receptor (ER) status, combined ER and 
progesterone-receptor status, number of positive nodes, type 
of previous chemotherapy, or use at any time of hormone-
replacement therapy (HRT).
There was also signiﬁ  cant superiority of exemestane 
in regard to distant DFS (HR 0.66; 95% CI 0.52–0.83; 
p = 0.0004) and in the risk for contralateral breast cancer 
(HR 0.44; 95 % CI 0.20–0.98).
The updated evaluation covering a median follow-up of 
55.7 months reinforced the earlier ﬁ  ndings and demonstrated 
that switching to exemestane remained signiﬁ  cantly superior 
to remaining on tamoxifen (Coombes et al 2007). A total of 
809 events contributing to the analysis of DFS had been reported 
(354 exemestane, 455 tamoxifen), leading to an unadjusted 
HR for the ITT group for DFS of 0.76 (95% CI 0.66–0.88; 
p = 0.0001) in favor of exemestane (Figure 2). In the ITT group, Therapeutics and Clinical Risk Management 2008:4(6) 1297
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4740 patients randomized*
8 unevaluable† 8 unevaluable†
4724 evaluable patients
2352 randomized to exemestane 2372 randomized to tamoxifen Efficacy analysis population
31 not treated 8 received tamoxifen 7 received exemestane 35 not treated
2320 received exemestane
1807 completed treatment 1832 completed treatment 506 did not complete
       treatment
251 adverse event/patient
       refusal
194 recurrence/death
61 protocol violation/
     LTFU/other
513 did not complete
       treatment
321 adverse event/patient
       refusal
33 recurrence/death
59 protocol violation/
     LTFU/other
2338 received tamoxifen Safety analysis population
Figure 1: Trial profile        
LTFU = lost to follow-up. *2 patients with duplicate patient identifiers were identified, thus the total number of patients randomised  is 2 fewer than proviously
reported. †Monitoring for regulatory submission has resulted in an inability to confirm the validity of data at one individual center. On that basis, it was agreed that 
no data from patients entered at that center (n = 16) be used in further analyses. 
      
Figure 1 IES-31-study: trial design. Modiﬁ  ed with permission from Coombes RC, Kilburn LS, Snowdon CF, et al 2007. Survival and safety of exemestane versus tamoxifen after 
2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet, 369:559–70. Copyright © 2007 Elsevier.
this HR translated into a 3.3% (95% CI 1.6–4.9) absolute 
improvement in DFS at 2.5 years after randomization, and 
a 3.4% (0.1–6.8) improvement 5 years after randomization. 
Adjusting for potential confounders did not substantially affect 
the estimates of treatment effect, and the size of beneﬁt for 
switching to exemestane was consistent across all subgroups 
and any tumor characteristic that was measured (Figure 3). 
Breast-cancer-free survival was also improved by switching to 
exemestane for the ITT group (HR 0.76; 95% CI 0.65–0.89, 
p = 0.004).
These data resulted in a survival beneﬁ  t. In the ITT 
analysis 222 deaths occurred in the exemestane and 
261 in the tamoxifen group, accounting for a relative risk 
reduction of 15% (p = 0.08) (Figure 4). Since the second 
analysis, previously unknown ER status was ascertained 
in 381 women. Of these, 122 were identiﬁ  ed as having 
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Figure 2 IES-31-study: Kaplan-Meier plots for disease-free survival (DFS;  ITT-population). Modiﬁ  ed with permission from Coombes RC, Kilburn LS, Snowdon CF,  et al 2007. 
Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet, 369:559–70. 
Copyright © 2007 Elsevier.Therapeutics and Clinical Risk Management 2008:4(6) 1298
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ER-negative tumors, and therefore, in addition to an ITT 
analysis, those with ER-negative tumors were excluded and 
further analysis carried out. After exclusion of ER-negative 
tumors and a protocol-deﬁ  ned adjustment for nodal status, 
chemotherapy use, and HRT use, the adjusted HR for death 
was 0.83 (95% CI 0.69–0.99, p = 0.04) (Figure 4). As also 
shown in the second analysis, exemestane was generally 
well tolerated, undesirable effects were usually mild to 
moderate.
The clinical beneﬁ  ts were achieved without a detrimental 
effect on quality of life (QOL), as demonstrated in 
the IES-QOL substudy (Fallowfield et al 2006). The 
switch from tamoxifen to exemestane neither increased 
nor decreased endocrine symptoms present after 2 to 3 
years of tamoxifen, and did not initiate signiﬁ  cant new 
symptoms.
NSABP B-33 study
In May 2001, the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) initiated a randomized, 
placebo-controlled, double-blind clinical trial to evaluate 
exemestane (25 mg/day orally) as extended adjuvant 
therapy (NSABP B-33). The trial included clinical stage 
T1–3 N 0–1 M 0 endocrine-sensitive postmenopausal breast 
cancer patients who completed at least 5 years of tamoxifen 
therapy and were disease-free at the time of tamoxifen 
discontinuation. The primary aim of the trial was to 
determine whether adjuvant exemestane, for 2 years, after 
5 years of tamoxifen therapy would prolong DFS compared 
with placebo. Secondary endpoints were OS and relapse-
free survival (RFS).
When accrual to the B-33 trial was initiated, no other 
information existed on beneﬁt from aromatase inhibitors 
in this setting. However, in October 2003, while accrual 
to B-33 was ongoing (1,598 patients had been accrued 
of 3,000 required), interim analysis results from another 
similarly designed trial (National Cancer Institute of Canada 
[NCIC] MA.17) demonstrated beneﬁt from letrozole in 
patients who had completed 5 years of tamoxifen became 
available (Goss et al 2003). As a consequence, the accrual 
to B-33 was stopped, the treatment assignment unblinded, 
and exemestane offered to women in the placebo group. 
At the time of unblinding, 1,598 patients had been randomly 
assigned; 72% in the exemestane group continued on 
exemestane and 44% in the placebo group elected to receive 
exemestane (Figure 5).
0.5 0.6 0.8 1.0 1.2
HR (95% CI)
Nodes– (2447)
Nodes+ (2089)
No previous chemotherapy (3182)
Previous chemotherapy (1542)
ER unknown (560)
ER + PgR– (742)
ER + PgR+ (2668)
ER + (4042)
Previous tamoxifen ≤2.5 years (2842)
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Age ≥70 years (1180)
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ITT
Favors exemestane Favors tamoxifen HR (95% CI)
0.74 (0.58–0.94)
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0.82 (0.63–1.06)
0.70 (0.56–0.87)
0.81 (0.63–1.04)
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p = 0.0001
+ = positive, – = negative. ER = oestrogen-receptor. PgR = progesterone-receptor. Forest plots display subgroup 
analyses depicting the HR as the centre of the box and 95% CI as a horizontal line, the box size being proportional 
to the precision of the estimate. 
Figure 3 IES-31-study: Subgroup analysis forest plot for disease-free survival (DFS;  ITT-population). Modiﬁ  ed with permission from Coombes RC, Kilburn LS, Snowdon CF, 
et al 2007. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet, 
369:559–70. Copyright © 2007 Elsevier.Therapeutics and Clinical Risk Management 2008:4(6) 1299
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Mamounas et al (2008) published the data of the 
outcome analysis with 30 months of median follow-up based 
on the original random assignment (ITT), yielding a 32%, 
borderline statistically signiﬁ  cant reduction in 4-year DFS 
(91% vs 89%; relative risk [RR] 0.68; p = 0.07) (Figure 6) 
and in a statistically signiﬁ  cant 56% decrease in 4-year RFS 
(96% vs 94%; RR = 0.44; p = 0.004). Toxicity, assessed 
up to time of unblinding, was acceptable for the adjuvant 
setting.
The reduction of DFS and RFS shown in the NSABP B 33 
trial are of a magnitude similar to that seen with the nonsteroidal 
AIs letrozole and anastrozole in the same setting. The NCIC 
MA.17 trial demonstrated a 42% reduction in recurrence with 
letrozole over placebo after 5 years of tamoxifen (Goss et al 
2003, 2005). These ﬁndings demonstrate that exemestane may 
provide another option for the extended adjuvant treatment of 
postmenopausal women with endocrine-sensitive breast cancer 
who complete 5 years of adjuvant tamoxifen.
The International Breast Cancer Study Group (IBCSG) is 
currently evaluating the role of exemestane (IBCSG 24-02/
BIG 2-02 [SOFT]), also in combination with GnRH analogs 
(IBCSG 25-02/BIG 3-02 [TEXT]) as adjuvant therapy for 
premenopausal women with endocrine-responsive breast cancer. 
Both studies are ongoing and results are not available yet.
Safety analysis
Overall tolerability
In general, exemestane therapy was well tolerated (Coombes 
et al 2004, 2007). Grade 3 or 4 adverse events were noted 
in 426 (18.4%) patients on exemestane and 411 (17.6%) 
on tamoxifen. At a median follow-up of 55.7 months, 
switching to exemestane was associated with signiﬁ  cantly 
fewer thromboembolic events (p = 0.004), endometrial 
hyperplasia (p  0.0001), uterine polyps (p  0.0001), and 
serious gynecological events (p = 0.0002) than continuing 
on tamoxifen.
Musculoskeletal pain, carpal tunnel syndrome, joint 
stiffness, paraesthesia, and arthralgia were reported more 
frequently in patients who switched to exemestane than in 
those who remained on tamoxifen. These effects emerged 
during the on-treatment period.
Myocardial infarctions were rare and occurred in 
31 (1.3%) exemestane-treated patients compared with 
19 (0.8%) tamoxifen-treated patients (p = 0.08). Any effect 
of treatment on risk of myocardial infarction seemed largely 
restricted to patients with a history of hypertension.
Menopausal symptoms
The phase III, randomized Tamoxifen Exemestane Adjuvant 
Multicenter (TEAM) trial is a prospective open-label 
randomized multicenter study designed specifically to 
evaluate the efﬁ  cacy of upfront adjuvant exemestane therapy 
for endocrine-sensitive postmenopausal early breast cancer 
in comparison with a crossover design using exemestane 
for 2 to 3 years after 2 to 3 years of tamoxifen. Patients 
received either tamoxifen 20 mg once daily orally for 2.5 or 
3 years followed by exemestane 25 mg once daily for 2 or 
2.5 years, or exemestane 25 mg once daily for 5 years, 
as a double-blind capsule for year 1, and open label for 
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Figure 4 IES-31-study:Kaplan-Meier plots for overall survival (OS; ITT-and oestrogen receptor positive/unknown population). Modiﬁ  ed with permission from Coombes RC, 
Kilburn LS, Snowdon CF, et al 2007. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised 
controlled trial. Lancet, 369:559–70. Copyright © 2007 Elsevier.
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4 years. Adjuvant hormonal treatment was initiated within 
10 weeks after surgery or completion of chemotherapy, 
whichever occurred last. The primary endpoint was deﬁ  ned 
as DFS, secondary endpoints included OS, incidence of new 
primary breast cancers, and safety parameters. In addition, 
5 substudies were used to separately analyze endometrial 
changes, lipid proﬁ  les, QOL, tolerability of therapy, and 
bone changes. A meta-analysis of overall drug efﬁ  cacy will 
use data from the combined substudies, but has not been 
published yet. However, results of the menopausal substudy 
as well as the bone data are available.
Jones et al (2007) assessed the prevalence of 10 common 
menopausal symptoms associated with either adjuvant 
tamoxifen or exemestane by self-report questionnaire 
administered to 1,614 consecutive patients at baseline and 
every 3 months during the ﬁ  rst year of the trial. Symptoms 
were categorized as none, mild, moderate, or severe. A hot 
ﬂ  ash score was calculated at each time point. Symptoms 
were analyzed by repeated-measures analysis of variance. 
Each time period was tested repeatedly against the 
baseline; an overall p-value was assigned for each reported 
symptom. The strengths of this study were the large number 
of women evaluated (N = 1,614), excellent compliance 
(7,286 completed questionnaires; 81% completion at 
12 months), and the double-blinded design.
The TEAM study showed at 12 months that patients 
receiving tamoxifen, versus those receiving exemestane, 
had a signiﬁ  cantly higher mean hot ﬂ  ush score (p = 0.0253) 
and more vaginal discharge (p  0.0001), whereas women 
under exemestane had more vaginal dryness (p = 0.0004) 
and decreased libido (p = 0.0343).
Thomas et al (2008) reported in an open-label, 
prospective, crossover study with 184 post-menopausal 
women experiencing hot ﬂ  ushes on adjuvant tamoxifen that 6 
weeks after switching to letrozole or exemestane, the primary 
end point, hot ﬂ  ush score, improved by 47.3% (p  0.001) 
compared to those reported on tamoxifen. The mean mood 
rating scale (MRS) score improved by 9.7% (p = 0.01). 
At 6 weeks, signiﬁ  cantly more women chose to remain 
on an AI (72% vs 22% preferring tamoxifen; p  0.001). 
At 3 months, 107 women (58%) preferred to remain on an AI, 
55 (30%) on tamoxifen, and 22 (12%) withdrew. These data 
suggest that in women suffering signiﬁ  cant adverse effects 
on tamoxifen, switching to an AI like exemestane improves 
hot ﬂ  ushes, mood, and quality of life.
Bone metabolism
The effects of a profound long-term estrogen deprivation 
achievable with the third-generation aromatase inhibitors in 
respect to the bone health has been a major concern.
Unlike nonsteroidal AIs, exemestane may exert 
beneﬁ  cial effects on bone through its primary metabolite 
17-hydroexemestane which expresses androgen agonistic 
activity. In fact, a preclinical study reported that the 
administration of exemestane to ovariectomized rats 
reduced both bone formation and resorption markers and 
attributed this pattern to the androgenicity of exemestane 
and its principal metabolite (Goss et al 2004). Lønning 
et al (2005) reported a signiﬁcant increased serum level 
and urinary excretion of bone resorption, but also bone 
formation markers in postmenopausal women with early 
breast cancer under exemestane 25 mg daily for 2 years 
in a double-blind setting which could be due to this 
androgenic effect.
In contrast, a subgroup of the IES 31-study focusing 
on the effect on bone health showed that within 6 months 
of switching to exemestane, bone mineral density (BMD) 
Original sample size 
(N = 3,000)
Accrual as of October
2003 (accrual stopped)
(n = 1,598)
Eligible 
(n = 1,577)
Eligible with follow-up
(n = 1,562)
Exemestane
(n = 783)
Continued on 
Exemestane
after unblining
(n = 560)
72%
Crossover to 
Exemestane 
after unblinding
(n = 344)
44%
 Placebo 
(n = 779)
Ineligible 
(n = 21)*
No follow-up
(n = 15)
(*) Reasons for ineligibility: abnormal pre-entry studies (n = 2);
required pre-entry studies not performed (n = 4); or not performed as
speciﬁed (n = 5); premenopausal status (n = 1); prior breast cancer
other than lobular carcinoma in situ (n = 2); prior recurrence (n = 1);
unknown/negative estrogen-/progesterone-receptor status (n = 3);
tamoxifen therapy outside  the prespeciﬁed range (n = 1); original
tumor not invasive carcinoma (n = 1); unknown margin status (n = 1).    
Figure 5 NSABP B-33-study:CONSORT diagram. Modiﬁ  ed with permission from 
Mamounas EP, Jeong JH, Wickerham DL, et al. 2008. Beneﬁ  t from exemestane as 
extended adjuvant therapy after 5 years of adjuvant tamoxifen:intention-to-treat 
analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin 
Oncol, 26:1965–71. Copyright © 2008 American Society of Clinical Oncology.Therapeutics and Clinical Risk Management 2008:4(6) 1301
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was lowered by 0.051 g/cm3 (2.7%; 95% CI 2.0–3.4; 
p  0.0001) at the lumbar spine and 0.025 g/cm3 (1.4%; 
0.8–1.9; p  0.0001) at the hip compared with baseline 
(Coleman et al 2007). However, BMD decreases were only 
1.0% (0.4–1.7; p = 0.002) and 0.8% (0.3–1.4; p = 0.003) in 
year 2 at the lumbar spine and hip, respectively (Figure 7). 
Further decreases were smaller and approached rates observed 
in a healthy age-matched population. No patient with BMD 
in the normal range at trial entry developed osteoporosis. 
Bone resorption and formation markers increased at all time 
points in women receiving exemestane (p  0.001). With 
a median follow-up in all IES participants (n = 4,274) of 
58 months, 162 (7%) and 115 (5%) patients in the exemestane 
and tamoxifen groups, respectively, had fractures (odds ratio 
1.45 [1.13–1.87]; p = 0.003).
These ﬁ  ndings are in accordance with the data of 
another study in postmenopausal patients switched to 
exemestane after 2 to 3 years of adjuvant treatment with 
tamoxifen, showing a marked increase in bone turnover 
markers with a consequent reduction in BMD (Gonelli 
et al 2007).This pattern of BMD is more evident at skeletal 
sites where trabecular bone prevails and is most likely 
due to rapid cessation of bone turnover suppression by 
tamoxifen.
These findings corroborate the results of the bone 
TEAM-substudy, evaluating 161 women receiving tamoxifen 
(N = 78) or exemestane (N = 83), showing a loss in absolute 
BMD under exemestane at 12 months (Hadji et al 2008). 
The difference was signiﬁ  cant at the spine (p = 0.0008 and 
hip (p = 0.04). However, during the second year of treatment, 
the rate of BMD loss slowed dramatically. All measured 
markers of bone formation and resorption show an increase 
with exemestane.
Lipid proﬁ  le
Given their mechanism of action, one might expect 
that AIs may have certain adverse effects on multiple 
estrogen-dependent metabolic functions such as lipid 
metabolism when compared with tamoxifen.
The beneﬁ  ts of receiving an AI are likely to outweigh 
the disadvantages of any changes to lipid profiles. 
However, when these compounds are used in early disease 
or in the prevention setting, an increase of 10% to 15% 
in circulating cholesterol and triglycerides may have a 
signiﬁ  cant impact on the risk of cardiovascular disease, 
and monitoring of blood lipid levels and instigation of 
lipid lowering treatment if required should be undertaken 
(Bundred 2005).
A subprotocol to the ATENA (Adjuvant post-
Tamoxifen Exemestane versus Nothing Applied) trial 
compared the effect of exemestane on the lipid proﬁ  le in 
the adjuvant setting to that of observation alone following 
deprivation of 5 to 7 years primary treatment with 
tamoxifen (Markopoulos et al 2005). In this open-label, 
randomized, parallel group study, 340 post-menopausal 
women with operable breast cancer who had been treated 
with tamoxifen for 5 to 7 years were randomized to either 
5 additional years of exemestane (25 mg/day; N = 172) or 
observation alone (N = 168).
Total serum triglycerides (TRG) levels were signiﬁ  cantly 
reduced compared with baseline for the exemestane and the 
observational arm. Both total cholesterol and low-density 
lipoprotein (LDL) concentrations signiﬁ  cantly increased 
above that of baseline values by 6 months, maintained 
through to 12 months, with no signiﬁ  cant difference between 
the two treatment arms. There was no signiﬁ  cant alteration 
observed for high-density lipoprotein (HDL) over time or 
between the two arms. In conclusion, switching patients to 
adjuvant exemestane treatment does not induce major effects 
on serum lipids.
Endometrial effects
A prospective open label randomized multicenter substudy 
was performed in the German TEAM Trial Group to test the 
hypothesis that the irreversible inactivation of aromatase by 
exemestane (EXE; N = 78) would result in less endometrial 
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proliferation than tamoxifen (TAM; N = 65) (Kieback 
et al 2006).
After a median follow-up of 727 (EXE) and 526 days 
(TAM), endometrial hyperplasia was observed in 11 patients 
in the exemestane-arm versus 45 patients under tamoxifen 
(p  0.0001). Time to endometrial hyperplasia was signiﬁ  cantly 
longer in the EXE group (p  0.0001); HR was 0.160 indicating 
an 84% risk reduction of hyperplasia in the EXE group. Only 
one patient underwent histological sampling in the EXE group 
(no hyperplasia) versus 18 in the TAM subset.
Cost effectiveness
Thompson et al (2007) performed an analysis of the cost-
effectiveness of switching to exemestane versus staying on 
tamoxifen based on the IES data. Because the trial data span 
a limited period of time and do not include information on 
resource utilization, the authors used modeling techniques 
and data from sources external to the IES to project long-term 
survival and economic costs.
A Markov model was developed to predict patients’ 
transitions across various health states based on treatment 
strategy (continuing tamoxifen vs switching to exemestane), 
breast cancer status (no recurrence, local or distant 
recurrence, contralateral breast cancer), and other related 
health events (osteoporosis, endometrial cancer, death). Rates 
of disease-related events (recurrence and contralateral breast 
cancer) were estimated using data from the IES. Survival and 
lifetime medical-care costs by type of disease-related event 
were estimated using SEER-Medicare data. The model was 
used to estimate direct costs (in 2004 US$7,724 per patient), 
life expectancy, quality-adjusted life-years (QALYs), and 
incremental cost-effectiveness.
Switching to exemestane versus continuing tamoxifen 
therapy was associated with an increased disease-free survival, 
QALYs (12.21 vs 11.89), and net discounted lifetime costs 
of cancer care ($12,124 vs $7,724 per patient). The incre-
mental cost-effectiveness ratio of exemestane was $20,100 
per QALY gained (95% CI $12,100, $59,000). According to 
the authors’ conclusion, the switch-to-exemestane strategy 
versus completing a 5-year course of tamoxifen is a cost-
effective use of health-care resources, despite the fact that the 
per-day cost of exemestane therapy is nearly 3 times higher 
than that of tamoxifen.
Conclusion for clinical implications
The data of the IES 31-trial demonstrated that switching 
to exemestane after 2 to 3 years of tamoxifen signiﬁ  cantly 
improves disease-free survival and reduces the chance of 
new disease in the contralateral breast or distant recurrence, 
independent of any tumor characteristics (Coombes 
et al 2007). As shown in the updated results, the early 
improvements in DFS noted in patients who switched to 
exemestane persist after treatment, and translate into a modest 
improvement in overall survival. In addition, the ﬁ  ndings of 
the IES also demonstrate that the beneﬁt of switching from 
tamoxifen to an AI in patients with endocrine-responsive 
breast cancer persists for some years after discontinuation 
of the AI.
So far, no data are available from trials that directly 
compare use of AI monotherapy with a sequential or switch 
strategy. Therefore, direct evidence from the sequential 
therapy arms of BIG 1–98 and from the TEAM trial 18 is 
awaited with keen interest to conclude on the value of the 
sequential strategy.
Exemestane appears to be different from other aromatase 
inhibitors with its less detrimental effect on bone after 
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12 months of treatment. However, the available data do 
not enable conﬁ  rmation that exemestane may have any 
substantial advantageous effects on bone with respect to 
the nonsteroidal aromatase inhibitors (Gonelli et al 2007). 
The data suggest that postmenopausal women switched from 
tamoxifen to exemestane should be monitored for bone loss in 
accordance with the American Society of Clinical Oncology 
recommendations (Hillner et al 2003), especially if other risk 
factors for osteoporosis are present.
The national (ie, AGO Breast Commission) and 
international guidelines recommend 3 strategies:
1.  upfront treatment with letrozole or anastrozole
2.  switching to exemestane or anastrozole after 2 to 3 years 
of tamoxifen
3.  extended adjuvant treatment with letrozole after 
completion of 5 years of tamoxifen
To date, the data are in favor of both upfront AIs or switch 
to an AI in patients already on tamoxifen for 2 to 3 years not 
having relapsed while on tamoxifen.
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